💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

BRIEF-Valeant Pharmaceuticals receives notice of default from bondholders due to delayed 10-K Filing

Published 2016-04-12, 05:08 p/m
© Reuters.  BRIEF-Valeant Pharmaceuticals receives notice of default from bondholders due to delayed 10-K Filing
BHC
-

April 12 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International
Inc VRX.TO :
* Valeant pharmaceuticals receives notice of default from
bondholders due to delayed 10-k filing
* On schedule to file its 10-k on or before april 29, 2016
* Says company has until june 11, 2016 to cure default by
filing 10-k
* Notice of default does not result in acceleration of any
of company's indebtedness
* Received a notice of default from holders of its 5.5%
notes due 2023 as a result of delay in company filing its form
10-k
* Says "company is on schedule to file its 10-k on or before
april 29, 2016"

Source text for Eikon: ID:nCNWfFrK0a
Further company coverage: VRX.TO

(Bengaluru Newsroom: +1 646 223 8780)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.